Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q2 2023 Earnings Conference Call August 15, 2023 8:00 AM ET
Company Participants
Alex Lobo - Investor Relations
Milton Werner - Chief Executive Officer
Joe Frattaroli - Chief Financial Officer
Conference Call Participants
Ed White - H.C. Wainwright
Operator
Good morning. Welcome to the Inhibikase Therapeutics Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Alex Lobo, Stern Investor Relations. Please go ahead.
Alex Lobo
Good morning and welcome to the Inhibikase Therapeutics second quarter 2023 financial results conference call and audio webcast. With me today is Dr. Milton Werner, Chief Executive Officer and Joe Frattaroli, Chief Financial Officer.
On Monday, August 14, 2023, Inhibikase issued a press release announcing financial results for the second quarter ended June 30, 2023. We encourage everyone to read yesterday’s press release as well as Inhibikase’s quarterly report on Form 10-Q, which is being filed with the SEC. The company’s press release and quarterly report are also available on Inhibikase’s website at inhibikase.com. In addition, this conference call is being webcast through the Investor Relations section of the company’s website and will be archived there for future reference.
Please note that certain information discussed on today’s call is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Participants are cautioned that this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, August 15, 2023. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company’s business. Information on potential risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this webcast, except as maybe required by applicable securities law.
With that said, I would now like to turn the call over to Dr. Milton Werner. Milton, you may begin.
Milton Werner
Thank you, Alex and thank you everyone for joining us today for Inhibikase Therapeutics second quarter 2023 earnings call. We are pleased with the progress we have made across our clinical programs in the first half of this year.
Our Phase 2 201 trial using IkT-148009 to treat Parkinson’s disease is screening and enrolling patients across 22 of up to 35 planned sites, with the first patient 12-week dosing regimen. Additionally, this quarter, we launched a public awareness campaign through of the 201trial.com that we believe will enable us to continue to drive enrollment in the trial. The trial website is being augmented with outreach to patient advocacy groups, caregiver networks, foundations and social media advertising throughout the United States.